EGFR and non-small cell lung carcinoma: Oral tyrosine kinase inhibitors (TKIs) have been shown to prolong progression-free survival in patients with advanced NSCLC harbouring a sensitising EGFR mutation compared with doublet chemotherapy in a number of clinical trials [3–5].